Cochrane condemned for 'bizarre' review of new hep C drugs

The Cochrane Collaboration has been condemned over its critical review of the new wave of hepatitis C anti-viral drugs, which it says have not been proven to save lives or prevent harm.

The review of 138 randomised controlled trials on the direct-acting antivirals (DAA) says there is little evidence they clear the virus from the body, only that they may clear the hepatitis C virus from the blood.

“Most trials primarily focused and assessed the effects of DAAs on sustained virological response; however, it is questionable if sustained virological response has any clinical relevance